These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2455591)

  • 1. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis.
    Droz JP; Kramar A; Ghosn M; Piot G; Rey A; Theodore C; Wibault P; Court BH; Perrin JL; Travagli JP
    Cancer; 1988 Aug; 62(3):564-8. PubMed ID: 2455591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR; Belitsky P; Millard OH; Lannon SG
    Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
    de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
    Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery.
    Vugrin D; Friedman A; Whitmore WF
    Cancer; 1984 Mar; 53(6):1440-5. PubMed ID: 6198071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
    Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
    J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
    de Wit R; Collette L; Sylvester R; de Mulder PH; Sleijfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Stoter G
    Br J Cancer; 1998 Nov; 78(10):1350-5. PubMed ID: 9823978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
    Stevens MJ; Norman AR; Dearnaley DP; Horwich A
    J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lens Culinaris Agglutinin-reactive Fraction of Alpha-fetoprotein as a Tumor Marker in a Patient With Nonseminomatous Germ Cell Tumor With Normal Alpha-fetoprotein Level.
    Sugiyama H; Takeshita H; Tachibana K; Hiranuma S; Takagi D; Kagawa M; Yano A; Okada Y; Morozumi M; Kawakami S
    Clin Genitourin Cancer; 2020 Jun; 18(3):e309-e311. PubMed ID: 31926880
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
    J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
    Toner GC; Geller NL; Lin SY; Bosl GJ
    Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
    Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
    Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
    J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
    Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
    Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group.
    Klepp O; Olsson AM; Henrikson H; Aass N; Dahl O; Stenwig AE; Persson BE; Cavallin-Ståhl E; Fosså SD; Wahlqvist L
    J Clin Oncol; 1990 Mar; 8(3):509-18. PubMed ID: 1689773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors.
    de Bruijn HW; Sleijfer DT; Schraffordt Koops H; Suurmeijer AJ; Marrink J; Ockhuizen T
    Cancer; 1985 Feb; 55(4):829-35. PubMed ID: 2578303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.
    Logothetis CJ; Swanson DA; Dexeus F; Chong C; Ogden S; Ayala AG; von Eschenbach AC; Johnson DE; Samuels ML
    J Clin Oncol; 1987 Jun; 5(6):906-11. PubMed ID: 2438389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
    Bosl GJ; Head MD
    Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
    Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Toner GC; Schraffordt Koops H; Mulders PF; Messemer JE; Ney K; Donohue JP
    J Clin Oncol; 1995 May; 13(5):1177-87. PubMed ID: 7537801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.